Literature DB >> 18815397

Drug-eluting or bare-metal stents for acute myocardial infarction.

Laura Mauri1, Treacy S Silbaugh, Pallav Garg, Robert E Wolf, Katya Zelevinsky, Ann Lovett, Manu R Varma, Zheng Zhou, Sharon-Lise T Normand.   

Abstract

BACKGROUND: Studies comparing percutaneous coronary intervention (PCI) with drug-eluting and bare-metal coronary stents in acute myocardial infarction have been limited in size and duration.
METHODS: We identified all adults undergoing PCI with stenting for acute myocardial infarction between April 1, 2003, and September 30, 2004, at any acute care, nonfederal hospital in Massachusetts with the use of a state-mandated database of PCI procedures. We performed propensity-score matching on three groups of patients: all patients with acute myocardial infarction, all those with acute myocardial infarction with ST-segment elevation, and all those with acute myocardial infarction without ST-segment elevation. Propensity-score analyses were based on clinical, procedural, hospital, and insurance information collected at the time of the index procedure. Differences in the risk of death between patients receiving drug-eluting stents and those receiving bare-metal stents were determined from vital-statistics records.
RESULTS: A total of 7217 patients were treated for acute myocardial infarction (4016 with drug-eluting stents and 3201 with bare-metal stents). According to analysis of matched pairs, the 2-year, risk-adjusted mortality rates were lower for drug-eluting stents than for bare-metal stents among all patients with myocardial infarction (10.7% vs. 12.8%, P=0.02), among patients with myocardial infarction with ST-segment elevation (8.5% vs. 11.6%, P=0.008), and among patients with myocardial infarction without ST-segment elevation (12.8% vs. 15.6%, P=0.04). The 2-year, risk-adjusted rates of recurrent myocardial infarction were reduced in patients with myocardial infarction without ST-segment elevation who were treated with drug-eluting stents, and repeat revascularization rates were significantly reduced with the use of drug-eluting stents as compared with bare-metal stents in all groups.
CONCLUSIONS: In patients presenting with acute myocardial infarction, treatment with drug-eluting stents is associated with decreased 2-year mortality rates and a reduction in the need for repeat revascularization procedures as compared with treatment with bare-metal stents. 2008 Massachusetts Medical Society

Entities:  

Mesh:

Year:  2008        PMID: 18815397     DOI: 10.1056/NEJMoa0801485

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  43 in total

1.  Comparison of vascular remodeling in patients treated with sirolimus-versus zotarolimus-eluting stent following acute myocardial infarction.

Authors:  Ki-Woon Kang; Young-Guk Ko; Dong-Ho Shin; Jung-Sun Kim; Byeong-Keuk Kim; Donghoon Choi; Yangsoo Jang; Myeong-Ki Hong
Journal:  Clin Cardiol       Date:  2011-12-12       Impact factor: 2.882

2.  First human trial of KW39 slotted-tube stents: for percutaneous coronary intervention.

Authors:  Minoru Tanaka; Nelson Hirokazu Tsuno; Kazuaki Mitsudo; Kazushige Kadota; Ryozo Tatami; Masayuki Kato; Kenichi Kato; Akihiko Nogami; Osamu Ishikawa; Koki Takahashi
Journal:  Tex Heart Inst J       Date:  2011

3.  A meta-analysis of randomized trials on clinical outcomes of paclitaxel-eluting stents versus bare-metal stents in ST-segment elevation myocardial infarction patients.

Authors:  Xiao-hong Pan; Ying-xue Chen; Mei-xiang Xiang; Geng Xu; Jian-an Wang
Journal:  J Zhejiang Univ Sci B       Date:  2010-10       Impact factor: 3.066

Review 4.  Are drug-eluting stents safe in the long term?

Authors:  Philippe Généreux; Roxana Mehran
Journal:  CMAJ       Date:  2008-12-23       Impact factor: 8.262

5.  Long-term outcomes of patients receiving drug-eluting stents.

Authors:  Andrew C Philpott; Danielle A Southern; Fiona M Clement; P Diane Galbraith; Mouhieddin Traboulsi; Merril L Knudtson; William A Ghali
Journal:  CMAJ       Date:  2008-12-18       Impact factor: 8.262

6.  Evaluating the effectiveness of a rapidly adopted cardiovascular technology with administrative data: the case of drug-eluting stents for acute coronary syndromes.

Authors:  Jerome J Federspiel; Sally C Stearns; Brett C Sheridan; Jack J Kuritzky; Laura P D'Arcy; Daniel J Crespin; Timothy S Carey; Joseph S Rossi
Journal:  Am Heart J       Date:  2012-08       Impact factor: 4.749

7.  Bare Metal Stents Versus Drug Eluting Stents: Where Do We Stand in 2015?

Authors:  Perwaiz M Meraj; Rajiv Jauhar; Avneet Singh
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-08

8.  Use of drug-eluting stents in acute myocardial infarction with persistent ST-segment elevation: results of the ALKK PCI-registry.

Authors:  Tobias Härle; Uwe Zeymer; Arne Kristian Schwarz; Claus Lüers; Matthias Hochadel; Harald Darius; Wolfgang Kasper; Karl Eugen Hauptmann; Dietrich Andresen; Albrecht Elsässer
Journal:  Clin Res Cardiol       Date:  2014-01-17       Impact factor: 5.460

9.  Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts.

Authors:  Laura Mauri; Treacy S Silbaugh; Robert E Wolf; Katya Zelevinsky; Ann Lovett; Zheng Zhou; Frederic S Resnic; Sharon-Lise T Normand
Journal:  Circulation       Date:  2008-10-13       Impact factor: 29.690

10.  Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.

Authors:  A Abelson; J D Ringe; D T Gold; J L Lange; T Thomas
Journal:  Osteoporos Int       Date:  2009-09-01       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.